Programs of Research – Pathogenesis
Each member needs to fill out this template to document current research projects.
Name: Delia Nelson
PhD? X Yes
Project title: Using agonist anti-CD40 monoclonal antibody as an anti-tumour immunotherapy
Aims: To test anti-CD40 antibody as a monotherapy or in combination with other therapeutic
modalities
Methods/techniques used: Murine models; human cell lines; flow cytometry; PCR, tissue culture
Progress to-date: See outcomes
Names of full and associate members linked to project: Connie Jackaman, S Cornwall
Research outcome/s:
Publications:
Jackaman C., Cornwall S., Graham P.T., and Nelson D.J. (2011). CD40-activated B cells contribute to
mesothelioma tumor regression. Immunology and Cell Biology. 89:255-267. Impact factor: 4.2.
Jackaman C. and Nelson D.J. (2012). Intra-tumoral interleukin-2/agonist CD40 antibody drives CD4independent resolution of treated-tumors and CD4-dependent systemic and memory responses. Cancer
Immunology and Immunotherapy. 61(4);549-560. Impact factor: 4.293.
Jackaman C., Lansley S., Allan J.E., Robinson B.W.S. and Nelson D.J. (2012). IL-2/CD40-driven NK cells
install and maintain potency in the anti-mesothelioma effector/memory phase. International
Immunology. DOI:10.1093/intimm/dxs005. Impact factor: 3.3.
Nelson D.J., Nowak A., Lake R and Robinson BWS. (Accepted June 2012). The use of agonistic anti-CD40
therapy in treatments for cancer. International Reviews of Immunology. Impact factor: 3.2.
Nelson D.J. (Accepted April 2012, to be published September 2012). Turning the tumor
microenvironment into a self vaccine site. Journal of OncoImmunology.